Short QT syndrome type 3: genes and variants
Explore variant evidence for Short QT syndrome type 3 across 3 analyzed proteins (KCNJ2, KCNH2, KCNQ1). Linked ClinVar records include 36 pathogenic or likely pathogenic variants, 222 variants of uncertain significance and 27 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Short QT syndrome type 3
KCNJ2: Inward rectifier potassium channel 2
Its inward-rectifier current stabilizes the resting membrane potential in cardiac and skeletal muscle and contributes to terminal cardiac repolarization. Loss-of-function variants cause Andersen-Tawil syndrome, while gain-of-function variants can cause short-QT syndrome.
28 ClinVar pathogenic / likely pathogenic and 174 uncertain variants in KCNJ2 have source records linked to Short QT syndrome type 3. Association strength is not clinical gene validity.
KCNH2: Voltage-gated inwardly rectifying potassium channel KCNH2
Its unusually rapid inactivation and slow deactivation shape the rapid delayed-rectifier current IKr, a major determinant of ventricular repolarization. Loss-of-function variants can prolong repolarization and cause long-QT syndrome, whereas gain-of-function variants can cause short-QT syndrome.
4 ClinVar pathogenic / likely pathogenic and 65 uncertain variants in KCNH2 have source records linked to Short QT syndrome type 3. Association strength is not clinical gene validity.
KCNQ1: Potassium voltage-gated channel subfamily KQT member 1
The protein forms the pore of a voltage-gated potassium channel that helps set electrical activity in heart muscle. Its partnerships with KCNE subunits also support normal function in the inner ear and other tissues, while KCNQ1 variants are linked to long-QT and short-QT syndromes.
4 ClinVar pathogenic / likely pathogenic and 10 uncertain variants in KCNQ1 have source records linked to Short QT syndrome type 3. Association strength is not clinical gene validity.
Where Short QT syndrome type 3 variants cluster
- KCNJ2 Selectivity filter (positions 142–147): 5 of 27 ClinVar pathogenic / likely pathogenic variants, 13.2× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Short QT syndrome type 3
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| KCNJ2 G144S | 144 | Pore-forming | Pathogenic / likely pathogenic (★★) |
| KCNJ2 T75M | 75 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 G144A | 144 | Pore-forming | Pathogenic / likely pathogenic (★★) |
| KCNJ2 G144D | 144 | Pore-forming | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R218W | 218 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R218P | 218 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R218L | 218 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R82Q | 82 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| KCNJ2 M307V | 307 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R312C | 312 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 G146S | 146 | Pore-forming | Pathogenic / likely pathogenic (★★) |
| KCNQ1 R259H | 259 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNQ1 R539W | 539 | Interaction with KCNE1 C-terminus | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R189G | 189 | Polyphosphoinositide (PIP2)-binding | Pathogenic / likely pathogenic (★★) |
| KCNJ2 M301R | 301 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNH2 N629S | 629 | Segment H5 | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R67Q | 67 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNQ1 R507W | 507 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 T75K | 75 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 T75R | 75 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 D78Y | 78 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 D78N | 78 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 T309I | 309 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 Y145C | 145 | Pore-forming | Pathogenic / likely pathogenic (★) |
| KCNJ2 G215D | 215 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 N216Y | 216 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 R260H | 260 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 D71V | 71 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 D172N | 172 | Transmembrane | Pathogenic / likely pathogenic (★) |
| KCNJ2 P186Q | 186 | Polyphosphoinositide (PIP2)-binding | Pathogenic / likely pathogenic (★) |
| KCNJ2 E299G | 299 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 T305A | 305 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNH2 Y43D | 43 | PAS | Pathogenic / likely pathogenic (★) |
| KCNH2 G47V | 47 | PAS | Pathogenic / likely pathogenic (★) |
| KCNH2 L86R | 86 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNQ1 F279I | 279 | Segment S5 | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Short QT syndrome type 3
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| KCNJ2 M301V | 301 | Cytoplasmic | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; M301R at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.861 |
| KCNJ2 G144V | 144 | Pore-forming | Conflicting reports (★) | +6: 5 other pathogenic changes within 3 positions; G144A at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| KCNJ2 R189K | 189 | Polyphosphoinositide (PIP2)-binding | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R189G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.99 |
| KCNJ2 M301L | 301 | Cytoplasmic | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; M301R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.72 |
| KCNJ2 G215C | 215 | Cytoplasmic | Uncertain (★) | +6: 5 other pathogenic changes within 3 positions; G215D at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| KCNJ2 G146D | 146 | Pore-forming | Uncertain (★) | +6: 5 other pathogenic changes within 3 positions; G146S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| KCNJ2 D78H | 78 | Cytoplasmic | Uncertain (★) | +6: 5 other pathogenic changes within 3 positions; D78Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| KCNJ2 N216I | 216 | Cytoplasmic | Uncertain (★) | +6: 5 other pathogenic changes within 3 positions; N216Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.99 |
| KCNJ2 R189T | 189 | Polyphosphoinositide (PIP2)-binding | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; R189G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
Which prediction tools work for Short QT syndrome type 3
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- EVE: 99 out of 100
- REVEL: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 97 out of 100
- CATVariant: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 95 out of 100
- MetaSVM: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 93 out of 100
- ESM1b (LLR): 87 out of 100
- phyloP: 72 out of 100
- SpliceAI: 43 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 43 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Andersen Tawil syndrome also has ClinVar records linked to KCNJ2 variants; they fall in the same places as the Short QT syndrome type 3 variants (34 pathogenic / likely pathogenic).
- Long QT syndrome also has ClinVar records linked to KCNH2 variants; they fall mostly in different places as the Short QT syndrome type 3 variants (114 pathogenic / likely pathogenic).
- Cardiac arrhythmia also has ClinVar records linked to KCNH2 variants; they fall mostly in different places as the Short QT syndrome type 3 variants (15 pathogenic / likely pathogenic).
- Long QT syndrome also has ClinVar records linked to KCNQ1 variants; they fall mostly in different places as the Short QT syndrome type 3 variants (175 pathogenic / likely pathogenic).
- Cardiac arrhythmia also has ClinVar records linked to KCNQ1 variants; they fall mostly in different places as the Short QT syndrome type 3 variants (49 pathogenic / likely pathogenic).
- Familial atrial fibrillation also has ClinVar records linked to KCNQ1 variants; they fall mostly in different places as the Short QT syndrome type 3 variants (8 pathogenic / likely pathogenic).
- Jervell and Lange-Nielsen syndrome also has ClinVar records linked to KCNQ1 variants; they fall mostly in different places as the Short QT syndrome type 3 variants (4 pathogenic / likely pathogenic).
Diseases related to Short QT syndrome type 3
- Long QT syndrome, also linked to KCNH2, KCNJ2 and KCNQ1
- Cardiac arrhythmia, also linked to KCNH2, KCNJ2 and KCNQ1
- Familial atrial fibrillation, also linked to KCNJ2 and KCNQ1
- Multiple sclerosis, also linked to KCNH2 and KCNQ1
- Type 2 diabetes mellitus, also linked to KCNQ1
- Diabetes mellitus, also linked to KCNQ1
- Andersen Tawil syndrome, also linked to KCNJ2
- Monogenic hearing loss, also linked to KCNQ1
- Epilepsy, also linked to KCNQ1
- Primary familial hypertrophic cardiomyopathy, also linked to KCNH2
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency, also linked to KCNH2
- Beckwith-Wiedemann syndrome, also linked to KCNQ1
Frequently asked questions
Which genes have records linked to Short QT syndrome type 3?
This view contains 3 analyzed proteins: KCNJ2, KCNH2, KCNQ1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 36 pathogenic or likely pathogenic variants, 222 variants of uncertain significance and 27 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 9 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 300 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center